INSTIL BIO INC (TIL)

US45783C2008 - Common Stock

10.64  +0.23 (+2.21%)

Fundamental Rating

2

Taking everything into account, TIL scores 2 out of 10 in our fundamental rating. TIL was compared to 588 industry peers in the Biotechnology industry. The financial health of TIL is average, but there are quite some concerns on its profitability. TIL does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TIL has reported negative net income.
TIL had a negative operating cash flow in the past year.
TIL had negative earnings in each of the past 5 years.
In the past 5 years TIL always reported negative operating cash flow.

1.2 Ratios

TIL's Return On Assets of -47.93% is in line compared to the rest of the industry. TIL outperforms 52.65% of its industry peers.
The Return On Equity of TIL (-69.12%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -47.93%
ROE -69.12%
ROIC N/A
ROA(3y)-39.98%
ROA(5y)-40.08%
ROE(3y)-52.91%
ROE(5y)-50.43%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for TIL has been reduced compared to 1 year ago.
The debt/assets ratio for TIL is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.42, we must say that TIL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TIL (-2.42) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.36 indicates that TIL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.36, TIL is doing worse than 71.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z -2.42
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 15.22 indicates that TIL has no problem at all paying its short term obligations.
TIL has a better Current ratio (15.22) than 90.77% of its industry peers.
A Quick Ratio of 15.22 indicates that TIL has no problem at all paying its short term obligations.
TIL's Quick ratio of 15.22 is amongst the best of the industry. TIL outperforms 90.77% of its industry peers.
Industry RankSector Rank
Current Ratio 15.22
Quick Ratio 15.22

More info and screens

1

3. Growth

3.1 Past

TIL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -292.64%.
EPS 1Y (TTM)-292.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q58.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 19.91% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.69%
EPS Next 2Y19.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TIL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

TIL's earnings are expected to grow with 19.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.91%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSTIL BIO INC

NASDAQ:TIL (4/19/2024, 7:19:40 PM)

10.64

+0.23 (+2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap69.16M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.93%
ROE -69.12%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 15.22
Quick Ratio 15.22
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-292.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y61.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y